Common drugs, vitamins, nutritional supplements and COVID‑19 mortality

Lehrer,Steven; Rheinstein,Peter H.

doi:10.3892/ijfn.2021.14

Common drugs, vitamins, nutritional supplements and COVID‑19 mortality

Authors:
- Steven Lehrer
- Peter H. Rheinstein
View Affiliations

Affiliations: Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA, Severn Health Solutions, Severna Park, MD 21146, USA
Published online on: March 1, 2021 https://doi.org/10.3892/ijfn.2021.14
Article Number: 4
Copyright: © Lehrer et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The FDA has approved only one drug, remdesivir, for the treatment of COVID‑19. The FDA has granted an emergency use authorization for the rheumatoid arthritis treatment drug, baricitinib (Olumiant), for the treatment of COVID‑19 in some cases. For this reason, investigators have paid considerable attention to the association between commonly used drugs and the outcome of patients with COVID‑19. Aspirin and ibuprofen have been reported to reduce the mortality rate. Omeprazole can increase mortality. In addition, some studies have demonstrated that famotidine diminishes mortality, while others have indicated that famotidine leads to a poorer prognosis. The present study used UK Biobank (UKB) data to assess the association of commonly used drugs with COVID‑19 mortality. Data processing was performed on Minerva, a Linux mainframe with Centos 7.6. The UK Biobank Data Parser (ukbb_parser) was used, a python‑based package that allows easy interfacing with the large UK Biobank dataset. The results revealed that aspirin and omeprazole were associated with an elevated mortality rate. Ibuprofen‑related mortality was lower than laxative‑related mortality. Aspirin users were also significantly older than other subjects. The association with mortality of cholesterol‑lowering medications, blood pressure‑lowering medications, hormone replacement and oral contraceptives in 134 female subjects revealed insignificant variability. The association of nutritional supplements in 238 subjects with mortality indicated that variability was insignificant. The lower mortality linked to the supplementation of vitamin D and vitamin B, presumably B complex, has been previously observed. On the whole, the present study demonstrates that although some of the associations described among drugs and COVID‑19 are not novel, the utility of a new source, UKB, may prove to be useful in further examining these associations.

View Figures

View References

1	Kim PS, Read SW and Fauci AS: Therapy for early COVID-19: A critical need. JAMA. 324:2149–2150. 2020.PubMed/NCBI View Article : Google Scholar
2	Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A, Jackson AM, McCurdy MT, Tabatabai A, Kumar G, Park P, et al: Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19. Anesth Analg: Oct 21, 2020 (Epub ahead of print). doi: 10.1213/ANE.0000000000005292.
3	Haque S, Jawed A, Akhter N, Dar SA, Khan F, Mandal RK, Areeshi MY, Lohani M and Wahid M: Acetylsalicylic acid (Aspirin): A potent medicine for preventing COVID-19 deaths caused by thrombosis and pulmonary embolism. Eur Rev Med Pharmacol Sci. 24:9244–9245. 2020.PubMed/NCBI View Article : Google Scholar
4	Mohamed-Hussein AA, Aly KM and Ibrahim MA: Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy? Med Hypotheses. 144(109975)2020.PubMed/NCBI View Article : Google Scholar
5	Pavoni V, Gianesello L, Pazzi M, Stera C, Meconi T and Frigieri FC: Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. Thromb Res. 196:313–317. 2020.PubMed/NCBI View Article : Google Scholar
6	Kelleni MT: Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 133(110982)2021.PubMed/NCBI View Article : Google Scholar
7	Kutti Sridharan G, Kotagiri R, Chandiramani VH, Mohan BP, Vegunta R, Vegunta R and Rokkam VR: COVID-19 and avoiding Ibuprofen. How good is the evidence? Am J Ther. 27:e400–e402. 2020.PubMed/NCBI View Article : Google Scholar
8	Rinott E, Kozer E, Shapira Y, Bar-Haim A and Youngster I: Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 26:1259.e5–1259.e7. 2020.PubMed/NCBI View Article : Google Scholar
9	Lee SW, Ha EK, Yeniova AÖ, Moon SY, Kim SY, Koh HY, Yang JM, Jeong SJ, Moon SJ, Cho JY, et al: Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: A nationwide cohort study with propensity score matching. Gut. 70:76–84. 2021.PubMed/NCBI View Article : Google Scholar
10	Mather JF, Seip RL and McKay RG: Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. Am J Gastroenterol. 115:1617–1623. 2020.PubMed/NCBI View Article : Google Scholar
11	Zhou J, Wang X, Lee S, Wu WK, Cheung BM, Zhang Q and Tse G: Proton pump inhibitor or famotidine use and severe COVID-19 disease: A propensity score-matched territory-wide study. Gut. 2020(323668)2020.PubMed/NCBI View Article : Google Scholar
12	Atkins JL, Masoli JA, Delgado J, Pilling LC, Kuo CL, Kuchel GA and Melzer D: Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci. 75:2224–2230. 2020.PubMed/NCBI View Article : Google Scholar
13	Zhu A, Salminen LE, Thompson PM and Jahanshad N: The UK Biobank Data Parser: A tool with built in and customizable filters for brain studies. Organization for Human Brain Mapping Rome, Italy, June 9-13, 2019.
14	Cangiano B, Fatti LM, Danesi L, Gazzano G, Croci M, Vitale G, Gilardini L, Bonadonna S, Chiodini I, Caparello CF, et al: Mortality in an Italian nursing home during COVID-19 pandemic: Correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests. Aging (Albany NY). 12:24522–24534. 2020.PubMed/NCBI View Article : Google Scholar
15	Tan CW, Ho LP, Kalimuddin S, Cherng BP, Teh YE, Thien SY, Wong HM, Tern PJ, Chandran M, Chay JW, et al: Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition. 79-80(111017)2020.PubMed/NCBI View Article : Google Scholar
16	Yuan S, Wang R, Chan JF, Zhang AJ, Cheng T, Chik KK, Ye ZW, Wang S, Lee AC, Jin L, et al: Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol. 5:1439–1448. 2020.PubMed/NCBI View Article : Google Scholar
17	Umhau J: Casting sunlight on an epidemic: Is vitamin D a critical host factor to prevent COVID-19? J Infect Dis: Mar 25, 2020 (Epub ahead of print).
18	Rubin R: Sorting out whether vitamin D deficiency raises COVID-19 risk. JAMA. 325:329–330. 2021.PubMed/NCBI View Article : Google Scholar
19	Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CS, Silva CR, Franco AS, Macedo MB, Dalmolin HH, et al: Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A Randomized Clinical Trial. JAMA: Feb 17, 2021. doi: 10.1001/jama.2020.26848.
20	De Flora S, Balansky R and La Maestra S: Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J. 34:13185–13193. 2020.PubMed/NCBI View Article : Google Scholar
21	Khanji MY, Aung N, Chahal CA and Petersen SE: COVID-19 and the UK Biobank-Opportunities and challenges for research and collaboration with other large population studies. Front Cardiovasc Med. 7(156)2020.PubMed/NCBI View Article : Google Scholar